12-Month Lab Check on GLP-1: Long-Term Assessment
One year of GLP-1 treatment -- your labs now tell the complete story of metabolic transformation.
The 12-month lab check is where the full impact of GLP-1 treatment becomes clear. By now, most patients have lost 15-20%+ of body weight and their blood work reflects a fundamentally different metabolic profile.
Recommended 12-Month Panel
Complete Annual Assessment
- CMP, lipid panel, HbA1c (core metabolic)
- TSH, free T4 (thyroid function)
- CBC with differential
- Liver panel (ALT, AST, ALP, GGT)
- Vitamin D, B12, folate, ferritin
- Fasting insulin, HOMA-IR
- Inflammatory markers (CRP, ESR)
- Uric acid
- Consider: cardiac panel, hormone panel
Typical 12-Month Results
12-Month Improvements
| Marker | Typical Change from Baseline |
|---|---|
| Body weight | 15-22% decrease |
| HbA1c | 0.8-2.0% decrease (often normal) |
| LDL cholesterol | 15-25% decrease |
| Triglycerides | 25-40% decrease |
| CRP | 40-60% decrease |
| Liver enzymes | Usually normalized |
| Blood pressure | 5-10 mmHg systolic decrease |
Planning for Maintenance
With strong 12-month results, discuss with your provider whether to continue current dose, reduce to maintenance dose, consider switching medications for cost optimization (e.g., tirzepatide to semaglutide for maintenance at $125/mo), and set the schedule for ongoing annual monitoring.
Your Best Year Yet
Join the patients transforming their metabolic health. Semaglutide $99/mo. Tirzepatide $125/mo through Trimi.
Get StartedMedical Disclaimer
Lab improvements are typical ranges; individual results vary. Always discuss results with your healthcare provider. Do not adjust medications without physician guidance.
More on GLP-1 lab monitoring
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).